--Okta Guides For Q2 EPS of $0.60-$0.61 on Revenue of $631-$633 Million, vs CIQ Analyst Consensus of $0.54/Share on Revenue of $617 Million-March 2024-www.financetom.com

--Okta Guides For Q2 EPS of $0.60-$0.61 on Revenue of $631-$633 Million, vs CIQ Analyst Consensus of $0.54/Share on Revenue of $617 Million

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

--Okta Guides For Q2 EPS of $0.60-$0.61 on Revenue of $631-$633 Million, vs CIQ Analyst Consensus of $0.54/Share on Revenue of $617 Million

May 29, 2024 1:31 PM

04:03 PM EDT, 05/29/2024 (MT Newswires) --

Price: 90.00, Change: -6.36, Percent Change: -6.60

Previous page： Arcutis Biotherapeutics Receives Approval in Canada for Skin Disease Cream Zoryve Next page： Analysis-Nestle CEO Freixe's turnaround plan faces challenge from weak consumer

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Arcutis Biotherapeutics Receives Approval in Canada for Skin Disease Cream Zoryve

Oct 18, 2024

08:48 AM EDT, 10/18/2024 (MT Newswires) -- Arcutis Biotherapeutics ( ARQT ) said Friday that its Arcutis Canada subsidiary has received regulatory approval from Health Canada for Zoryve topical foam 0.3% to treat seborrheic dermatitis in patients aged 9 and older. The approval was based on data from a phase 3 study, along with findings from a phase 2 study,...

Analysis-Nestle CEO Freixe's turnaround plan faces challenge from weak consumer

Oct 18, 2024

LONDON (Reuters) - Nestle's plans under new CEO Laurent Freixe to restructure and sharpen its focus on its top brands were welcomed by investors, but executing a turnaround strategy against a backdrop of weak consumer demand will be a tough task. After replacing Mark Schneider as CEO last month, Freixe set out plans on Thursday to revamp the executive board,...

Gilead voluntarily withdraws urothelial cancer drug in US

Oct 18, 2024

Oct 18 (Reuters) - Gilead Sciences ( GILD ) said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients with a type of urothelial cancer after consultation with the regulator. (Reporting by Sneha S K) ...

Activist investor Jana Partners builds about 5% stake in Lamb Weston, WSJ reports

Oct 18, 2024

Oct 18 (Reuters) - Activist investor Jana Partners has built a stake of about 5% in frozen fries supplier Lamb Weston ( LW ) , the Wall Street Journal reported on Friday, citing people familiar with the matter. ...